Major bleeding risk in elderly patients age ≥ 75 years with non-valvular atrial fibrillation initiating oral anticoagulants: A 'real-world' comparison of warfarin, apixaban, dabigatran, or rivaroxaban

被引：0
|
作者：
Keshishian, Allison [1 ]
Kamble, Shital [1 ]
Pan, Xianying [1 ]
Burns, Leah [1 ]
Mardekian, Jack [1 ]
Horblyuk, Ruslan [1 ]
Hamilton, Melissa [1 ]
Squibb, Bristol-Myers [1 ]
机构：
[1] Bristol Myers Squibb Co, New York, NY 10154 USA
来源：
PHARMACOTHERAPY | 2016年 / 36卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
32E
引用
收藏
页码：E213 / E213
页数：1
相关论文
共 50 条
  • [21] Real-world comparison of major bleeding risk associated with direct oral anticoagulants or warfarin in patients with non-valvular atrial fibrillation: a systematic review and network meta-analysis
    Deitelzweig, S. B.
    Farmer, C.
    Luo, X.
    Li, X.
    Vo, L.
    Mardekian, J.
    Fahrbach, K.
    Ashaye, A.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 577 - 578
  • [22] Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies
    Deitelzweig, S.
    Farmer, C.
    Luo, X.
    Vo, L.
    Li, X.
    Hamilton, M.
    Horblyuk, R.
    Ashaye, A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (09) : 1583 - 1594
  • [23] Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin
    Lin, Iris
    Horblyuk, Ruslan
    Mardekian, Jack
    Park, Sang Hee
    Kamble, Shital
    Hamilton, Melissa
    Abdulsattar, Younos
    Petkun, William
    Menzin, Joseph
    Lip, Gregory Y.
    [J]. CIRCULATION, 2016, 134
  • [24] Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
    Lip, Gregory Y. H.
    Pan, Xianying
    Kamble, Shital
    Kawabata, Hugh
    Mardekian, Jack
    Masseria, Cristina
    Phatak, Hemant
    [J]. PLOS ONE, 2018, 13 (04):
  • [25] REAL-WORLD COMPARISON OF INPATIENT BLEEDING RISK, BLEEDING-RELATED HOSPITALIZATION RATES AND COSTS AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS ON APIXABAN, DABIGATRAN, RIVAROXABAN: COHORTS COMPRISING NEW INITIATORS AND/OR SWITCHERS FROM WARFARIN
    Tepper, Ping
    Mardekian, Jack
    Masseria, Cristina
    Horblyuk, Ruslan
    Kamble, Shital
    Hamilton, Melissa
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 662 - 662
  • [26] Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis
    Deitelzweig, S.
    Farmer, C.
    Luo, X.
    Li, X.
    Vo, L.
    Mardekian, J.
    Fahrbach, K.
    Ashaye, A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (03) : 487 - 498
  • [27] Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation: A Real-World Setting
    Fontaine, Gabriel V.
    Mathews, Katy D.
    Woller, Scott C.
    Stevens, Scott M.
    Lloyd, James F.
    Evans, R. Scott
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2014, 20 (07) : 665 - 672
  • [28] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
    Adeboyeje, Gboyega
    Sylwestrzak, Gosia
    Barron, John J.
    White, Jeff
    Rosenberg, Alan
    Abarca, Jacob
    Crawford, Geoffrey
    Redberg, Rita
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (09): : 968 - 978
  • [29] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [30] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    [J]. PLOS ONE, 2019, 14 (08):
12345